{"schema_version":"secwatch.filing_event.v1","accession":"0001964738-25-000094","form_type":"8-K","ticker":"SOLV","cik":"0001964738","company_name":"Solventum Corp","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.168562+00:00","generated_at":"2026-05-16T13:06:09.691564+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Solventum CEO reviews first standalone year; cites volume growth, acquisitions, $1B buyback","bullets":["Six consecutive quarters of positive volume growth; full-year 2025 outlook raised multiple times.","Completed sale of Purification & Filtration segment; used proceeds to reduce debt and strengthen balance sheet.","First strategic acquisition: Acera Surgical, expanding Advanced Wound Care portfolio.","Announced $1 billion share repurchase program, balancing capital allocation strategy.","Exited over 35% of 3M transition service agreements; progressing on supply chain separation and ERP cutover."],"urls":{"canonical":"https://secwatch.observer/filing/0001964738-25-000094","json":"https://secwatch.observer/filing/0001964738-25-000094.json","markdown":"https://secwatch.observer/filing/0001964738-25-000094.md","text":"https://secwatch.observer/filing/0001964738-25-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964738/000196473825000094/0001964738-25-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964738/000196473825000094/solv-20251216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:06:09.691564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}